168 related articles for article (PubMed ID: 26814680)
1. Identification of N-(6-mercaptohexyl)-3-(4-pyridyl)-1H-pyrazole-5-carboxamide and its disulfide prodrug as potent histone deacetylase inhibitors with in vitro and in vivo anti-tumor efficacy.
Wen J; Bao Y; Niu Q; Yang J; Fan Y; Li J; Jing Y; Zhao L; Liu D
Eur J Med Chem; 2016 Feb; 109():350-9. PubMed ID: 26814680
[TBL] [Abstract][Full Text] [Related]
2. Novel thiol-based histone deacetylase inhibitors bearing 3-phenyl-1H-pyrazole-5-carboxamide scaffold as surface recognition motif: Design, synthesis and SAR study.
Wen J; Niu Q; Liu J; Bao Y; Yang J; Luan S; Fan Y; Liu D; Zhao L
Bioorg Med Chem Lett; 2016 Jan; 26(2):375-379. PubMed ID: 26706171
[TBL] [Abstract][Full Text] [Related]
3. Discovery of Selective Histone Deacetylase 6 Inhibitors Using the Quinazoline as the Cap for the Treatment of Cancer.
Yang Z; Wang T; Wang F; Niu T; Liu Z; Chen X; Long C; Tang M; Cao D; Wang X; Xiang W; Yi Y; Ma L; You J; Chen L
J Med Chem; 2016 Feb; 59(4):1455-70. PubMed ID: 26443078
[TBL] [Abstract][Full Text] [Related]
4. A novel small molecule hybrid of vorinostat and DACA displays anticancer activity against human hormone-refractory metastatic prostate cancer through dual inhibition of histone deacetylase and topoisomerase I.
Yu CC; Pan SL; Chao SW; Liu SP; Hsu JL; Yang YC; Li TK; Huang WJ; Guh JH
Biochem Pharmacol; 2014 Aug; 90(3):320-30. PubMed ID: 24915421
[TBL] [Abstract][Full Text] [Related]
5. 4-Indolyl-N-hydroxyphenylacrylamides as potent HDAC class I and IIB inhibitors in vitro and in vivo.
Mehndiratta S; Wang RS; Huang HL; Su CJ; Hsu CM; Wu YW; Pan SL; Liou JP
Eur J Med Chem; 2017 Jul; 134():13-23. PubMed ID: 28395150
[TBL] [Abstract][Full Text] [Related]
6. 1-Arylsulfonyl-5-(N-hydroxyacrylamide)tetrahydroquinolines as potent histone deacetylase inhibitors suppressing the growth of prostate cancer cells.
Liu YM; Lee HY; Chen CH; Lee CH; Wang LT; Pan SL; Lai MJ; Yeh TK; Liou JP
Eur J Med Chem; 2015 Jan; 89():320-30. PubMed ID: 25462248
[TBL] [Abstract][Full Text] [Related]
7. Innovative DNA-Targeted Metallo-prodrug Strategy Combining Histone Deacetylase Inhibition with Oxidative Stress.
McGivern TJP; Slator C; Kellett A; Marmion CJ
Mol Pharm; 2018 Nov; 15(11):5058-5071. PubMed ID: 30192548
[TBL] [Abstract][Full Text] [Related]
8. Design, synthesis and evaluation of novel HDAC inhibitors as potential antitumor agents.
Cheng J; Qin J; Guo S; Qiu H; Zhong Y
Bioorg Med Chem Lett; 2014 Oct; 24(19):4768-4772. PubMed ID: 25182565
[TBL] [Abstract][Full Text] [Related]
9. Development and therapeutic impact of HDAC6-selective inhibitors.
Dallavalle S; Pisano C; Zunino F
Biochem Pharmacol; 2012 Sep; 84(6):756-65. PubMed ID: 22728920
[TBL] [Abstract][Full Text] [Related]
10. Identification of a series of substituted 2-piperazinyl-5-pyrimidylhydroxamic acids as potent histone deacetylase inhibitors.
Angibaud P; Van Emelen K; Decrane L; van Brandt S; Ten Holte P; Pilatte I; Roux B; Poncelet V; Speybrouck D; Queguiner L; Gaurrand S; Mariën A; Floren W; Janssen L; Verdonck M; van Dun J; van Gompel J; Gilissen R; Mackie C; Du Jardin M; Peeters J; Noppe M; Van Hijfte L; Freyne E; Page M; Janicot M; Arts J
Bioorg Med Chem Lett; 2010 Jan; 20(1):294-8. PubMed ID: 19906529
[TBL] [Abstract][Full Text] [Related]
11. Discovery of novel cyclin-dependent kinase (CDK) and histone deacetylase (HDAC) dual inhibitors with potent in vitro and in vivo anticancer activity.
Cheng C; Yun F; Ullah S; Yuan Q
Eur J Med Chem; 2020 Mar; 189():112073. PubMed ID: 31991336
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis and biological evaluation of 4-anilinothieno[2,3-d]pyrimidine-based hydroxamic acid derivatives as novel histone deacetylase inhibitors.
Yang W; Li L; Ji X; Wu X; Su M; Sheng L; Zang Y; Li J; Liu H
Bioorg Med Chem; 2014 Nov; 22(21):6146-55. PubMed ID: 25261927
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis, and biological evaluation of 1, 3-disubstituted-pyrazole derivatives as new class I and IIb histone deacetylase inhibitors.
Yao Y; Liao C; Li Z; Wang Z; Sun Q; Liu C; Yang Y; Tu Z; Jiang S
Eur J Med Chem; 2014 Oct; 86():639-52. PubMed ID: 25218912
[TBL] [Abstract][Full Text] [Related]
14. Effect of C7-substitution of 1-arylsulfonyl-5-(N-hydroxyacrylamide)indolines on the selectivity towards a subclass of histone deacetylases.
Lee HY; Wang LT; Li YH; Pan SL; Chen YL; Teng CM; Liou JP
Org Biomol Chem; 2014 Nov; 12(44):8966-76. PubMed ID: 25277250
[TBL] [Abstract][Full Text] [Related]
15. Discovery of pyridone-based histone deacetylase inhibitors: approaches for metabolic stability.
Cho M; Choi E; Yang JS; Lee C; Seo JJ; Kim BS; Oh SJ; Kim HM; Lee K; Park SK; Kwon HJ; Han G
ChemMedChem; 2013 Feb; 8(2):272-9. PubMed ID: 23292995
[TBL] [Abstract][Full Text] [Related]
16. A series of camptothecin prodrugs exhibit HDAC inhibition activity.
Zhu Q; Yu X; Shen Q; Zhang Q; Su M; Zhou Y; Li J; Chen Y; Lu W
Bioorg Med Chem; 2018 Sep; 26(16):4706-4715. PubMed ID: 30115492
[TBL] [Abstract][Full Text] [Related]
17. Computer-aided identification of new histone deacetylase 6 selective inhibitor with anti-sepsis activity.
Yoo J; Kim SJ; Son D; Seo H; Baek SY; Maeng CY; Lee C; Kim IS; Jung YH; Lee SM; Park HJ
Eur J Med Chem; 2016 Jun; 116():126-135. PubMed ID: 27060764
[TBL] [Abstract][Full Text] [Related]
18. Defining the mechanism of action and enzymatic selectivity of psammaplin A against its epigenetic targets.
Baud MG; Leiser T; Haus P; Samlal S; Wong AC; Wood RJ; Petrucci V; Gunaratnam M; Hughes SM; Buluwela L; Turlais F; Neidle S; Meyer-Almes FJ; White AJ; Fuchter MJ
J Med Chem; 2012 Feb; 55(4):1731-50. PubMed ID: 22280363
[TBL] [Abstract][Full Text] [Related]
19. Platinum(IV) prodrugs multiply targeting genomic DNA, histone deacetylases and PARP-1.
Xu Z; Hu W; Wang Z; Gou S
Eur J Med Chem; 2017 Dec; 141():211-220. PubMed ID: 29031068
[TBL] [Abstract][Full Text] [Related]
20. Psammaplin A is a natural prodrug that inhibits class I histone deacetylase.
Kim DH; Shin J; Kwon HJ
Exp Mol Med; 2007 Feb; 39(1):47-55. PubMed ID: 17334228
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]